# ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
Canonical URL: https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-discuss-second-quarter-2026-financial-results-on-august-7-f8a7cc57
Ticker: ANIP
Company: ANI Pharmaceuticals
Source: ANI Pharmaceuticals
Published: 2026-07-24 10:50 EST
## Summary

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will...

## Article Body
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET.

Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.

To view the webcast, please click here . Links to access the webcast and conference call will also be available on the “Events & Presentations” page of the Company’s website at https://www.anipharmaceuticals.com , under the “Investors” section. A replay of the event will remain accessible for up to one year.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations: Irina Koffler, Vice President, Investor Relations T: 917-734-7387 E: Irina.koffler@anipharmaceuticals.com

Media Relations: Argot Partners T: 212-600-1494 E: ani@argotpartners.com

SOURCE: ANI Pharmaceuticals, Inc.
## Recent Company News
- 2026-07-24 10:50 EST — [ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-discuss-second-quarter-2026-financial-results-on-august-7-f8a7cc57) — Source: ANI Pharmaceuticals
- 2026-07-16 20:34 EST — [ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-intent-to-appeal-rulings-in-cg-oncology-matter-62a30dad) — Source: ANI Pharmaceuticals
- 2026-07-13 10:50 EST — [ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-positive-six-month-topline-data-from-the-phase-4-o-658a24f6) — Source: ANI Pharmaceuticals
- 2026-05-27 10:50 EST — [ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conferenc-f9d25fa3) — Source: ANI Pharmaceuticals
- 2026-05-08 10:50 EST — [ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-reports-first-quarter-2026-financial-results-and-raises-2026-8805534e) — Source: ANI Pharmaceuticals
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)